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Abstract
Introduction: Mutations in BRCA1 and BRCA2 confer high risks of breast cancer and ovarian cancer. The risk prediction 
algorithm BOADICEA (Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm) may be used 
to compute the probabilities of carrying mutations in BRCA1 and BRCA2 and help to target mutation screening. 
Tumours from BRCA1 and BRCA2 mutation carriers display distinctive pathological features that could be used to better 
discriminate between BRCA1 mutation carriers, BRCA2 mutation carriers and noncarriers. In particular, oestrogen 
receptor (ER)-negative status, triple-negative (TN) status, and expression of basal markers are predictive of BRCA1 
mutation carrier status.
Methods: We extended BOADICEA by treating breast cancer subtypes as distinct disease end points. Age-specific 
expression of phenotypic markers in a series of tumours from 182 BRCA1 mutation carriers, 62 BRCA2 mutation carriers 
and 109 controls from the Breast Cancer Linkage Consortium, and over 300,000 tumours from the general population 
obtained from the Surveillance Epidemiology, and End Results database, were used to calculate age-specific and 
genotype-specific incidences of each disease end point. The probability that an individual carries a BRCA1 or BRCA2 
mutation given their family history and tumour marker status of family members was computed in sample pedigrees.
Results: The cumulative risk of ER-negative breast cancer by age 70 for BRCA1 mutation carriers was estimated to be 
55% and the risk of ER-positive disease was 18%. The corresponding risks for BRCA2 mutation carriers were 21% and 
44% for ER-negative and ER-positive disease, respectively. The predicted BRCA1 carrier probabilities among ER-positive 
breast cancer cases were less than 1% at all ages. For women diagnosed with breast cancer below age 50 years, these 
probabilities rose to more than 5% in ER-negative breast cancer, 7% in TN disease and 24% in TN breast cancer 
expressing both CK5/6 and CK14 cytokeratins. Large differences in mutation probabilities were observed by combining 
ER status and other informative markers with family history.
Conclusions: This approach combines both full pedigree and tumour subtype data to predict BRCA1/2 carrier 
probabilities. Prediction of BRCA1/2 carrier status, and hence selection of women for mutation screening, may be 
substantially improved by combining tumour pathology with family history of cancer.
Introduction
Genetic testing for BRCA1  and  BRCA2  has important
clinical implications: individuals found to carry muta-
tions in these genes can be carefully monitored and
receive preventive therapies including oophorectomy or
mastectomy [1-6]. As genetic testing is expensive and
may be associated with adverse psychological effects for
the individual and their family, testing is only appropriate
for those at highest risk of carrying mutations.
Several models have been developed for predicting risk
of carrying BRCA1 or BRCA2 mutation and subsequently
developing breast cancer [7]. These models generally
include information on occurrence and age of diagnosis
of breast cancer and other cancers in individuals and
their families [7]. Breast tumours arising in carriers of
BRCA1 or BRCA2 mutations, however , also differ from
one another and from sporadic tumours in terms of their
pathological characteristics, including those assessed
morphologically or by immunohistochemistry [8-12].
Incorporating information about the pathology of breast
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tumours in the proband or family members into risk-pre-
diction algorithms may result in improved discrimination
between BRCA1 mutation carriers, BRCA2 mutation car-
riers and nonmutation carriers, and provide a more accu-
rate basis for identifying those individuals that may
benefit from genetic testing.
Numerous studies have linked the absence of oestrogen
receptor (ER) expression in breast tumours with BRCA1
mutation carrier status using different laboratory meth-
ods, anti-ER antibodies, and cut-off points for ER staining
[13-22]. In the largest study to date, the Breast Cancer
Linkage Consortium (BCLC) reported that ER-negativity
- defined by <1% of breast cancer cells expressing detect-
able ER by immunohistochemistry - conferred an age-
adjusted odds ratio of 13.98 (95% confidence interval, 7.1
to 27.7; P < 0.0001) for BRCA1 mutation carrier status
c o m p a r e d  w i t h  c o n t r o l s  u n s e l e c t e d  f o r  f a m i l y  h i s t o r y
(FH) [10]. Furthermore, the ER status was found to be the
most significant risk factor in multiple regression analy-
ses including other factors that are individually signifi-
cant predictors of BRCA1 status. These factors included
progesterone receptor, human epidermal growth factor
receptor 2 (HER2), mitotic count, lymphocyte infiltra-
tion, and continuous pushing margins [10].
The triple-negative (TN) tumours are negative for ER,
progesterone receptor, and HER2, and they define a sub-
set of ER-negative disease. Subsets of TN tumours also
express high-molecular-weight cytokeratins (CKs) (for
example, CK5/6 and CK14), also referred to as basal CKs.
Expression of basal CKs in TN tumours has been shown
to provide additional information predictive of BRCA1
status [11]. The distribution of ER status in breast
tumours and CK expression amongst TN tumours from
BRCA2 mutation carriers appears to be similar to that in
tumours from the population overall [10,11]. HER2-posi-
tive tumours have been shown less common in both
BRCA1 and BRCA2 mutation carriers than in noncarriers
[10].
We previously developed a risk-prediction algorithm
for familial breast cancer and ovarian cancer - the Breast
and Ovarian Analysis of Disease Incidence and Carrier
Estimation Algorithm (BOADICEA) - which can be used
to compute the probabilities of carrying BRCA1  and
BRCA2  mutations and the probabilities of developing
breast cancer or ovarian cancer in the future [23]. BOA-
DICEA models the effects of BRCA1 and BRCA2 muta-
tions as well as a polygenic component representing the
joint multiplicative effect of a large number of genes each
of small effect [24,25]. BOADICEA has recently been
extended to incorporate the associations between BRCA1
and BRCA2 mutations and other cancer risks (such as
prostate cancer, pancreatic cancer and male breast can-
cer) [23], and has been shown to discriminate well
between mutation carriers and noncarriers in a large
series of families identified through UK genetic clinics
[7,26]. In the present report we propose a method for
incorporating breast tumour pathology information into
the BOADICEA risk-prediction model.
Materials and methods
Age-specific distribution of ER status and distribution of 
other markers
Data from the BCLC [10,11] were used to obtain the age-
specific proportions of ER-negative and ER-positive
tumours, and the proportions of TN tumours and CK5/6-
expressing and/or CK14-expressing tumours for BRCA1
or  BRCA2  carriers or controls. Breast cancer patients
with  BRCA1  and  BRCA2  mutations were identified
through families with multiple relatives diagnosed with
breast cancer or ovarian cancer. Data on 182 tumours in
BRCA1 mutation carriers from 119 families, 62 tumours
from BRCA2 mutation carriers from 35 families, and 109
control women with breast cancer who were unselected
for FH and not tested for mutation carrier status were
available.
Details of the methods used to determine tumour
marker expression are described by Lakhani and col-
leagues [10,11]. Briefly, assays were performed at a single,
quality-assured laboratory, and both the proportion of
tumour cells staining with ER, progesterone receptor,
HER2, CK5/6 or CK14 antibodies and the intensity of
staining as assayed by immunohistochemistry were
recorded [10,11]. The present work had been carried out
under local ethical approval. Owing to the sparse data on
BRCA2 tumours, and since the proportion of ER-positive
tumours were not significantly different from that in con-
trols [10], we assumed in the model that the age-specific
proportions of ER-positive tumours and ER-negative
tumours were the same as the proportions in the general
population.
Age-specific proportions of ER-negative cancers and
ER-positive cancers in the general population were
obtained from the Surveillance Epidemiology, and End
Results (SEER) database, a large population-based US
breast cancer registry [27]. Data for the years 1990 to
2006 (n = 326,839) were used. Data were coded as ER-
positive, ER-negative, or borderline. All analyses were
restricted to females of white ethnicity with invasive
breast cancer.
Statistical methods
Extending BOADICEA to incorporate tumour pathology
BOADICEA models the genetic susceptibility to breast
cancer in terms of BRCA1, BRCA2 and a polygenic com-
ponent representing the combined multiplicative effect of
several loci, each of small effect [23].Mavaddat et al. Breast Cancer Research 2010, 12:R28
http://breast-cancer-research.com/content/12/3/R28
Page 3 of 12
The breast cancer incidence for individual i is assumed
to depend on the underlying genotype through a model of
the form:
where λ0(t) is the baseline incidence at age t, Gi(t) is the
log relative risk corresponding to the major genotype
(that is, BRCA1 carrier, BRCA2 carrier or nonmutation
carrier) at age t, and Pi(t) is the age-dependent polygenic
effect assumed to be normally distributed with mean zero
and variance σ2(t). The polygenic component is approxi-
mated by the hypergeometric polygenic model [28].
The incidence of ovarian cancer is modelled in a similar
manner, but without a polygenic component.
The probabilities of developing breast cancer and ovar-
ian cancer are assumed to be independent, conditional on
the underlying genetic effects. Cancer incidences in
BOADICEA are calendar and cohort specific. The overall
age-specific incidences, averaged over all major geno-
types and polygenotypes, are constrained to agree with
the population incidences for England and Wales [29-35].
The BOADICEA model is implemented in the pedigree
analysis program MENDEL v3.3 [36]. Additional model
description and the model parameter estimates can be
found in our previous publication [23].
To incorporate tumour phenotypes, we considered
breast cancer subtypes as different disease end points.
For example, to incorporate the ER status, the total
observed breast cancer incidence was assumed to be:
where μ(t) is the incidence of ER-positive disease and
ν(t) is the incidence of ER-negative disease. We also
assumed that the probabilities of developing ER-negative
or ER-positive breast cancer are independent, conditional
on the underlying genotype. We assumed that the poly-
genic component Pi(t) was identical for both ER-negative
and ER-positive disease (that is, represented by the same
set of polygenes conferring the same relative risks),
although in principle this assumption could be relaxed.
The incidence for each individual i at age t therefore fol-
lows a model of the form:
where  μi(t) and νi(t) are the major genotype-specific
incidences for ER-positive and ER-negative disease,
respectively, for individual i.
Given the existing genotype-specific (BRCA1 carriers,
BRCA2 carriers, and noncarriers) incidences in BOADI-
CEA and the age-specific distribution of ER status in
breast tumours from the BCLC and SEER data, our aim
was to derive separate genotype-specific incidences for
ER-positive disease and ER-negative disease. These were
obtained by constraining the overall BRCA1 and BRCA2
incidences over ER status and polygenic effects to equal
the average breast cancer incidence for BRCA1  and
BRCA2 mutation carriers, estimated previously in BOA-
DICEA; and by constraining the overall incidence over
ER status, major gene (BRCA1 carriers, BRCA2 carriers
and noncarriers) and polygenic effects to agree with the
population breast cancer incidences. Separate genotype-
specific incidences were derived for TN ER-negative dis-
ease and non-TN ER-negative disease as well as for CK5/
6- and/or CK14-expressing and non-expressing TN
tumours using a similar approach. Details of the method
are provided in Additional file 1.
The derived incidences were used in the penetrance
calculations whenever information on the relevant
tumour marker status was available. For individuals with
no marker status information, penetrance calculations
use the total breast cancer incidences (as in the standard
BOADICEA model implementation [23]). The genetic
model is therefore fully specified by the BRCA1  and
BRCA2 mutation frequencies, the polygenic variance and
genotype-specific incidences for each type of disease.
BRCA1 and BRCA2 mutation carrier probabilities
The probability that an individual carries a BRCA1  or
BRCA2 mutation given FH and marker status (for exam-
ple, ER status), was computed as follows:
where P(BRCAj, FH, ER) is the probability of observing
the family with the particular FH and ER status, and the
proband carrying a BRCA j mutation (BRCA j = BRCA1
carrier, BRCA2 carrier, or noncarrier). These correspond
to pedigree likelihoods generated using the MENDEL
program [36].
Calculations for example pedigrees
We investigated the effect of incorporating tumour phe-
notypic information on the mutation carrier probabilities
using a variety of different scenarios. Carrier probabilities
were calculated in simple pedigrees for scenarios where
the marker status of tumours is unknown, or is known in
one or more members of a family. For simplicity, we
assumed that there was no follow-up after the age of diag-
nosis of cancer in each case.
Results
ER status of tumours from mutation carriers and unselected 
breast cancers in the general population
Age-specific proportions of ER-negative tumours in
BRCA1 mutation carriers and BRCA2 mutation carriers
derived from the BCLC dataset are presented in Table 1.
These proportions were obtained for ER status defined as
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positive where >1% of cells stained with anti-ER antibody
in immunohistochemistry assays. Similar results were
obtained when a combination of the proportion of cells
staining and a staining intensity equivalent to an Allred
score of 2 - a score shown to correspond to clinical
response to Tamoxifen [37-39] - was used (data not
shown). Data for age categories >70 years were sparse for
BRCA1 carriers, and we extrapolated data from the age
category 60 to 69 years for this group. Data for BRCA2
carriers were sparse in all age groups, resulting in jumps
in proportions between adjacent intervals (Table 1). We
therefore used population data [27] for BRCA2 carriers in
our analyses, as BRCA2 carriers have been shown to have
similar ER status distribution to unselected controls [10].
The age-specific proportions of ER-negative invasive
breast cancers from white females in the general popula-
tion obtained from the SEER database are shown in Fig-
ure 1. As previously reported, the proportion of ER-
negative tumours decreases with age [40].
Expression of other markers in tumours from mutation 
carriers and unselected controls
The proportions of TN tumours amongst ER-negative
tumours and of CK-expressing tumours among TN
tumours derived from the BCLC dataset are presented in
Table 2. These proportions were obtained for progester-
one receptor, CK5/6 or CK14 - defined as positive when
>1% of cells stained with the specific antibodies in immu-
nohistochemistry - and for HER2, where the majority of
cells showed a strong complete membrane staining
(equivalent to score 3 on the DAKO scoring system)
[10,11]. Owing to sparse data, we used a constant propor-
tion for expression of these tumour markers across all
ages at diagnosis of breast cancer. As CK expression
among TN tumours in BRCA2 carriers was similar to the
distribution among TN tumours in breast cases unse-
lected for FH and not tested for mutation (P > 0.05), we
used data from these controls for BRCA2 carriers in our
analyses.
Breast cancer subtype-specific risks
ER-specific incidences were calculated for each of the five
birth cohorts considered in BOADICEA. The resulting
incidences (averaged over all polygenotypes) of ER-posi-
tive and ER-negative breast cancers in BRCA1 carriers,
BRCA2 carriers and noncarriers for women born after
1950 are shown in Figure 2. The breast cancer incidence
curve in BRCA1  mutation carriers follows closely the
shape of the incidence curve for ER-negative disease (Fig-
ure 2a). This increases rapidly with age until about age 50
years but decreases gradually after this age. This pattern
is similar to the incidence of ER-negative disease in non-
carriers (Figure 2c). In contrast, the shape of the overall
breast cancer incidence curve in BRCA2 mutation carri-
ers is similar to that for ER-positive disease, where inci-
dence increases with age, with an inflexion at about age
50 years (Figures 2b). This is also consistent with the age-
specific pattern of ER-positive disease in noncarriers
(Figure 2c) and in unselected controls [40].
Figure 3 shows the corresponding average cumulative
risks of developing ER-positive and ER-negative breast
cancer by genotype. The probabilities of developing ER-
positive and ER-negative breast cancer for BRCA1 muta-
tion carriers by age 70 were calculated to be 18% and 55%,
respectively. The corresponding risks for BRCA2 muta-
tion carriers were 44% and 21% for ER-positive disease
and ER-negative disease, respectively. Subtype-specific
incidences for TN tumours and basal CK-expressing or
non-expressing TN tumours, and the corresponding
average cumulative risks of developing these tumours, are
provided in Additional file 2 (Supplementary figures S1 to
S6).
Prediction of BRCA1 and BRCA2 carrier probabilities
Figure 4 shows the predicted BRCA1 and BRCA2 carrier
probabilities for an individual, ignoring FH information.
Compared with the risks when the ER status of the
tumour is unknown, the BRCA1 carrier probabilities are
higher at all ages when the tumour is known to be ER-
negative, and are lower when the tumour is known to be
ER-positive (Figure 4a). For example, for a breast cancer
diagnosed at age 30, the carrier probability is estimated to
be 0.05 when the ER status is unknown, 0.11 when the
tumour is ER-negative and 0.01 when the tumour is ER-
positive.
Table 1: Oestrogen receptor-negative tumours as a proportion of total tumours in BRCA1 and BRCA2 mutation carriers
Carrier <30 years old 30 to 39 years 
old
40 to 49 years 
old
50 to 59 years 
old
60 to 69 years 
old
>70 years old
BRCA1 0.93 0.91 0.86 0.89 0.83 0.83a
BRCA2a 0.44 0.26 0.47 0.14 0.20 0.15
Data from the Breast Cancer Linkage Consortium (BCLC) [10]. aAs numbers were sparse, data were extrapolated from the nearest age group 
for BRCA1 carriers in updating the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm, and population data 
were substituted for BCLC data for BRCA2 carriers.Mavaddat et al. Breast Cancer Research 2010, 12:R28
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Knowledge of the TN status and basal marker expres-
sion further influences mutation carrier probabilities
(Figure 4b to 4d). For example, for breast cancer diag-
nosed at age 30, the BRCA1 carrier probability is esti-
mated to be 0.19 when the tumour is TN and 0.02 when
the tumour is ER-negative but not TN (Figure 4b). If both
basal markers CK5/6 and CK14 are expressed on a TN
tumour, the probability of carrying a BRCA1 mutation is
0.64 (Figure 4c). If neither CK is expressed on a TN
tumour when both have been tested for, however, the car-
rier probability is 0.04. Carrier probabilities for the sce-
nario where a test is available only for CK5/6 are also
shown (Figure 4c). Carrier probabilities for CK14-posi-
tive and CK14-negative tumours when a test is available
only for CK14 were almost identical to those obtained
when a test was available only for CK5/6 (data not
Figure 1 Proportion of oestrogen receptor-negative tumours from the general population. Oestrogen receptor (ER)-negative tumours as a 
proportion of all invasive breast cancers tested for ER expression in unselected females from the general population. Data from the Surveillance Epi-
demiology, and End Results database 1990 to 2006 [27].
Table 2: Proportion of each tumour subtype in BRCA1 and BRCA2 mutation carriers and unselected controls
Tumour phenotype Controlsa BRCA1 carriers BRCA2 carriers
TN (among ER-negative cases) 0.53 0.90 0.86
CK5/6-expressing and CK14-expressing TNb, c 0.14 0.49 0.38d
Either CK5/6-expressing or CK14-expressing TNb, c 0.24 0.30 0.13d
CK5/6-expressing TNb (only CK5/6 tested) 0.26 0.64 0.38d
CK14-expressing TNb ( o n l y  C K 1 4  t e s t e d ) 0 . 2 70 . 6 30 . 5 0
Data from Breast Cancer Linkage Consortium [11]. CK, cytokeratin; ER, oestrogen receptor; TN, triple negative. aControls were breast cancer 
cases unselected for family history and untested for mutation. bAs a proportion of all TN tumours. cBoth the CK5/6 status and the CK14 status 
have been tested. dAs numbers were sparse, proportions from controls were used in updating the Breast and Ovarian Analysis of Disease 
Incidence and Carrier Estimation Algorithm.Mavaddat et al. Breast Cancer Research 2010, 12:R28
http://breast-cancer-research.com/content/12/3/R28
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shown). The TN mutation status also influences BRCA2
mutation carrier probabilities (Figure 4d).
We also estimated carrier probabilities considering
both tumour markers and FH. Table 3 and Additional file
2 (Supplementary tables S1 and S2) show mutation car-
rier probabilities in a simple family with an affected
mother and an affected (proband) daughter. Knowledge
of the ER status of either tumour substantially influences
the mutation carrier probabilities. Notably, the later the
age at breast cancer diagnosis, the greater the relative
change in the BRCA1 mutation carrier probability. For
example, if the mother is 70 years old when diagnosed
with breast cancer, there is a threefold increase in muta-
tion carrier probability when the tumour is ER-negative
relative to when the ER status of the tumour is unknown.
If the mother is 40 years old when diagnosed, the increase
is less than twofold. In some cases, carrier mutation prob-
abilities for BRCA2 are also altered when information on
Figure 2 Incidence rates of oestrogen receptor-negative disease, 
oestrogen receptor-positive disease and all breast cancers. Inci-
dence rates per 100,000 individuals of oestrogen receptor (ER)-nega-
tive disease, ER-positive disease and all breast cancers in (a) BRCA1 
carriers, (b) BRCA2 carriers and (c) noncarriers, corresponding to wom-
en born after 1950.
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Figure 3 Average cumulative risk for oestrogen receptor-nega-
tive disease, oestrogen receptor-positive disease and all breast 
cancers. Average cumulative risk for oestrogen receptor (ER)-negative 
disease, ER-positive disease and all breast cancers in (a) BRCA1 carriers, 
(b) BRCA2 carriers, and (c) noncarriers, corresponding to women born 
after 1950.
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pathology of the tumour is available, because the BRCA1
and BRCA2 carrier probabilities are interdependent.
Figure 5 shows mutation carrier probabilities for a
hypothetical pedigree in which sequentially more patho-
logical information is available for a family member.
Mutation carrier probabilities are influenced by addi-
tional information. For example, if the tumour is TN, the
probability of carrying a BRCA1 mutation is increased. If
the tumour is ER-negative but not TN, however, the
probability of carrying a BRCA1 mutation is even less rel-
ative to when the tumour is ER-negative but of unknown
TN status.
Mutation screening for BRCA1 and BRCA2 is not 100%
sensitive and can vary depending on the mutation screen-
ing methods used. BOADICEA takes into account the
reduced sensitivity of mutation testing (assumed to be
70% for BRCA1 and 80% for BRCA2 for the purposes of
the example [23]). Figure 6 shows a pedigree in which the
proband had been tested for mutations in BRCA1  or
BRCA2. As expected, the residual probability of carrying
a BRCA1 mutation is markedly higher if the tumour in
either the proband or the mother is known to be ER-neg-
ative.
Discussion
We extended the BOADICEA model of genetic suscepti-
bility to breast cancer and ovarian cancer to incorporate
breast tumour pathology information - in particular, ER
Figure 4 Influence of tumour pathology on mutation carrier probabilities for a single affected individual. Mutation carrier probabilities for a 
single affected individual with no knowledge of family history of breast cancer: BRCA1 carrier probabilities are shown in relation to (a) oestrogen re-
ceptor (ER) status, (b) tumour-negative (TN) status, when the tumour is known to be ER-negative, and (c) cytokeratin (CK)5/6 and/or CK14 expression 
when the tumour is known to be TN. In (c) scenarios where both basal markers have been tested (**) or where only CK5/6 has been tested (*) are 
shown. BRCA2 carrier probabilities are shown in relation to (d) TN status when the tumour is known to be ER-negative.
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Table 3: Carrier mutation probabilities when the ER status of the mother is unknown, negative or positive
Mother's age at diagnosis
Proband 
age at 
diagnosis
Mother's ER 
status
30 years 40 years 50 years 60 years 70 years
BRCA 1 BRCA2 BRCA1 BRCA2 BRCA1 BRCA2 BRCA1 BRCA2 BRCA1 BRCA2
30 years Unknown 0.45 0.16 0.24 0.14 0.15 0.10 0.09 0.09 0.06 0.10
ER-negative 0.63 0.11 0.46 0.10 0.36 0.08 0.25 0.08 0.19 0.09
ER-positive 0.13 0.25 0.08 0.17 0.04 0.11 0.04 0.10 0.03 0.10
40 years Unknown 0.23 0.14 0.11 0.10 0.07 0.07 0.04 0.06 0.03 0.07
ER-negative 0.38 0.11 0.24 0.08 0.18 0.06 0.12 0.05 0.09 0.06
ER-positive 0.05 0.16 0.03 0.10 0.02 0.07 0.02 0.06 0.01 0.07
50 years Unknown 0.12 0.08 0.06 0.06 0.04 0.04 0.02 0.04 0.02 0.04
ER-negative 0.22 0.08 0.14 0.05 0.11 0.04 0.07 0.03 0.06 0.04
ER-positive 0.02 0.09 0.01 0.06 0.01 0.04 0.01 0.04 0.01 0.04
60 years Unknown 0.06 0.07 0.03 0.04 0.02 0.03 0.01 0.03 0.01 0.04
ER-negative 0.11 0.06 0.07 0.04 0.06 0.03 0.04 0.03 0.03 0.04
ER-positive 0.01 0.07 0.01 0.05 0.00 0.03 0.00 0.03 0.00 0.04
70 years Unknown 0.03 0.07 0.01 0.05 0.01 0.03 0.01 0.03 0.00 0.04
ER-negative 0.06 0.07 0.04 0.05 0.03 0.03 0.02 0.03 0.02 0.04
ER-positive 0.01 0.07 0.00 0.05 0.00 0.03 0.00 0.03 0.00 0.04
Both mother and proband are affected and the age of diagnosis of cancer in each case is the same as the age of last follow-up. Figures in italics 
represent genotype-specific risk when the oestrogen (ER) status is unknown. Bold figures indicate genotype-specific risk <10% when the ER 
status is unknown, but >10% when the ER status is known.
status. We divided breast cancer into distinct disease end
points and used data on the proportion of ER-negative
and ER-positive tumours in BRCA1 and BRCA2 carriers
and the general population to derive age-specific inci-
dences of ER-negative and ER-positive disease. Informa-
tion on the TN status and expression of basal markers on
TN tumours was also included in the model. Incorporat-
ing information on tumour pathology influences the pre-
dicted probabilities of carrying a BRCA1  or  BRCA2
mutation, in particular BRCA1, and may therefore have
implications for genetic testing and clinical decision-
making. The methodology presented here can in princi-
ple be applied to incorporate information in risk models
for other diseases where the disease can be divided into
distinct phenotypes such as different tumour sites in col-
orectal cancer [41,42] or subphenotypes of Crohn's dis-
ease [43].
Data on the distribution of ER status for BRCA1  or
BRCA2  b r e a s t  c a n c e r  t u m o u r s  w e r e  o b t a i n e d  f r o m  a
study conducted by the BCLC [10]. The ER status was
measured by immunohistochemistry in a single research
laboratory. A potential concern is that this assay may not
be representative of typical assessment of ER status con-
ducted in routine practice. The overall proportion of ER-
positive tumours in the control series of the BCLC study,
albeit relatively small, was however similar to that in the
SEER series, suggesting there is little relative bias in the
prevalence of ER-positivity. In addition, the cases in the
BCLC study were predominantly drawn from multiple
breast cancer families and this might have influenced the
ER status, although there is no evidence to support an
association between ER status and FH [44]. The number
of mutation carriers was also relatively small (182 BRCA1
mutation carriers and 64 BRCA2 mutation carriers). The
age-specific proportions of ER prevalence are therefore
somewhat imprecise. In the final analyses we based the
BRCA2 estimates on the proportion of ER-positive and
ER-negative tumours in the general population data, due
to lack of precision in the age-specific estimates in the
BCLC data. Data from larger studies, such the Consor-
tium of Investigators of Modifiers of BRCA1/2 [45], may
provide more precise estimates and improve the model-
ling of BRCA2 in the future.Mavaddat et al. Breast Cancer Research 2010, 12:R28
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To derive ER disease-specific incidences for nonmuta-
tion carriers we used the general population data from
the SEER database combined with the BCLC data on
m u t a t i o n  c a r r i e r s .  D a t a  o n  E R  s t a t u s  i n  S E E R  w e r e
obtained from medical records. The ER status was
recorded as either positive or negative without reference
to how these definitions were derived. These data may,
however, be more representative of clinical situations
where laboratories differ in the sensitivity with which
they measure ER expression and cut-off points and scor-
ing systems for ER positivity vary. As age-specific data
were used, variation in ER expression according to age at
diagnosis in control tumours is captured in our model.
The observed proportion of ER-negative tumours in
BCLC data among unselected controls under age 70 were
33.5%. The corresponding expected number of ER-nega-
tive tumours in the SEER database would be 35.9%. Data
on TN status and cytokeratin expression in the general
population were not available in these larger datasets and
were derived from unselected controls from the BCLC.
We derived genotype-specific incidences for develop-
ing different pathological subtypes of breast cancer using
estimates of the genotypic relative risks, mutation fre-
quencies in the general population, estimates of the poly-
genic distribution and the distributions of tumour
pathology markers. For this purpose, we used estimates
from published studies and registry data. Uncertainty
surrounds each of these parameters, however, and a
degree of measurement error may also be associated with
the determination of pathological markers. Although in
principle it may be possible to calculate confidence inter-
vals for the derived disease-specific incidences or carrier
probabilities, this would be complex due to the unknown
correlation structure between the parameters entering
the model. The derived incidences are therefore based on
the best currently available estimates. The cumulative
risks presented in Figure 3 do not take into account com-
peting risks of dying from nonbreast cancer causes.
These risks may therefore be somewhat higher than a
woman would face in reality as they assume survival to
the relevant age.
Our results show that incorporating tumour marker
information into BOADICEA may result in the better dis-
crimination between BRCA1  carriers,  BRCA2  carriers
and nonmutation carriers. As expected, individuals with
ER-negative tumours, or with ER-negative tumours diag-
Figure 5 Mutation carrier probabilities for a pedigree where se-
quentially more tumour pathology information is available. CK, 
cytokeratin; ER, oestrogen receptor; TN, triple negative.
Tumour marker status BRCA1 BRCA2
Unknown 0.04 0.05
ER-negative 0.11 0.05
ER-positive 0.01 0.05
Triple negative 0.18 0.07
ER-negative non-TN 0.03 0.02
TN CK5/6 and CK14-positive† 0.47 0.05
TN Either CK5/6 or CK14-positive† 0.21 0.06
TN CK-negative† 0.07 0.07
*Both mother and proband are affected and the age of diagnosis of cancer in 
each case is the same as the age of last follow-up.  Marker status of the 
mother’s tumour are shown.
† Both CK 5/6 and CK14 have been tested
Boxes indicate that genotype-specific risk is less than 10% when tumour 
marker status is unknown but higher than 10% where marker status is 
known.  
45 BC 40
60
60
BC 45
Figure 6 Influence of oestrogen receptor status on carrier proba-
bilities when the proband tested negative for mutations. ER, oe-
strogen receptor.
Before
Mutation test 
Mutation test
Negative*
ER status BRCA1 BRCA2 BRCA1 BRCA2
Unknown 0.16 0.21 0.07 0.06
Proband ER-negative 0.35 0.17 0.17 0.05
Proband ER-positive 0.04 0.24 0.01 0.06
Unknown 0.16 0.21 0.07 0.06
Mother ER-negative 0.38 0.16 0.18 0.05
Mother ER-positive 0.05 0.24 0.02 0.06
*sensitivity 70% for BRCA1 and 80% for BRCA2 mutations
Boxes indicate that genotype-specific risk is less than 10% when ER status 
is unknown but higher than 10% where ER status is known.  
BC 45
BC 60
60
BC 45
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nosed in their family members, are predicted to have a
higher BRCA1 mutation carrier probability. The current
National Institute for Clinical Excellence guidelines rec-
ommend that an affected family member is screened for
mutation if the predicted carrier probability for muta-
tions in BRCA1 or BRCA2 combined is at least 20% [46].
Knowledge of the ER status may therefore affect the deci-
sion to offer testing. For example, in a pedigree with an
affected daughter and mother with ages of diagnosis at 40
and 50 years, respectively, the combined mutation carrier
probabilities are 0.14 when the ER status is unknown but
0.24 if the mother's tumour is ER-negative. Similarly, the
presence of an ER-positive tumour in the family may
result in combined BRCA1 and BRCA2 carrier probabili-
ties <20%.
Information on the TN status and expression of basal
cytokeratins can further influence mutation carrier prob-
abilities. In our example, the BRCA1  mutation carrier
probability is increased over fourfold when the mother's
tumour is ER-CK14+CK5/6+ as compared with when it is
ER-negative, but information on basal CK is unavailable.
For a random 30-year-old breast cancer patient, the
BRCA1 mutation carrier probability is approximately 10
times greater for a patient with ER-CK14+CK5/6+ versus
ER-CK- breast tumour. Lakhani and colleagues argued
previously that the use of CK in combination with ER sta-
tus may provide a more specific test for BRCA1 carrier
status than ER alone, because ER-negative tumours are
more frequently observed amongst control tumours than
are basal CKs [11]. Our results further highlight the
potentially important role of basal CKs in addition to ER
status for risk prediction.
In the present model we assumed that the polygenic
component is identical for both ER-negative and ER-posi-
tive disease and for tumours of other subtypes; that is, the
polygenes confer the same relative risk by disease sub-
type. Studies that have evaluated the familial relative risks
of breast cancer by the ER status of the proband have in
general found no significant differences in the risks for
ER-negative disease and ER-positive disease [47-54]. In
addition, the segregation analysis of Antoniou and col-
leagues estimated similar polygenic variances of breast
cancer risk for BRCA1 and BRCA2 mutation carriers [23].
Recent studies, however, have demonstrated that many of
the common breast cancer susceptibility variants are
associated more strongly with ER-positive disease [55-
58]. Further, Antoniou and colleagues have shown that
modifying loci associated with BRCA2 cancers, but not
with BRCA1 carriers, parallel those associated with ER-
positive disease in the general population [55,59]. The
polygenotypes for ER-positive and ER-negative thus can-
not be perfectly correlated, but the extent of the correla-
t i o n  i s  n o t  k n o w n .  T h i s  m a y  a f f e c t  r i s k  p r e d i c t i o n  i n
circumstances where the tumour subtype is available for
more than one individual in a family. In principle, the
methods we presented can be extended to allow for dif-
ferent polygenic components on ER-negative and ER-
positive disease or other tumour subtypes once these can
be estimated.
Conclusions
We have developed a method for incorporating tumour
marker information into risk-prediction models by subdi-
viding the overall disease into different disease end points
and have implemented this method in BOADICEA to
incorporate tumour ER status, TN status, and expression
of basal markers. This will be implemented in the BOA-
DICEA web interface for use in genetic counselling. The
inclusion of phenotypic markers associated with BRCA1
status should improve risk prediction in breast cancer.
Additional material
Abbreviations
BCLC: Breast Cancer Linkage Consortium; BOADICEA: Breast and Ovarian Analy-
sis of Disease Incidence and Carrier Estimation Algorithm; CK: cytokeratin; ER:
oestrogen receptor; FH: family history; HER2: human epidermal growth factor
receptor 2; SEER: Surveillance Epidemiology; and End Results; TN: triple nega-
tive.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
NM, DFE and ACA contributed to the conception and execution of the project.
NM carried out the analysis and wrote the manuscript. SRL was lead patholo-
gist for the BCLC study. TRR contributed to discussions. ACA and DFE super-
vised the analysis and participated in writing the manuscript.
Additional file 1 Extending BOADICEA to incorporate tumour pathol-
ogy. Details of methods for extending BOADICEA to incorporate tumour 
pathology [60].
Additional file 2 Subtype-specific risks and carrier probabilities. Sup-
plementary figure S1 shows the incidence rate of ER-negative, TN disease, 
and ER-negative non-TN disease: incidence rate per 100,000 individuals in 
(a) BRCA1 carriers, (b) BRCA2 carriers and (c) noncarriers, corresponding to 
women before after 1950. Supplementary figure S2 shows average cumula-
tive risk for ER-negative disease, TN disease and ER-negative non-TN dis-
ease: average cumulative risk for (A) BRCA1 carriers, (b) BRCA2 carriers and (c) 
noncarriers, corresponding to women born after 1950. Supplementary fig-
ure S3 shows the incidence rate of ER-negative, TN, CK-expressing and non-
expressing TN disease (both CKs tested): incidence rate per 100,000 individ-
uals in (a) BRCA1 carriers, (b) BRCA2 carriers and (c) noncarriers, correspond-
ing to women born after 1950. Supplementary figure S4 shows the average 
cumulative risk for ER-negative, TN and CK-expressing and non-expressing 
disease (both CKs tested): average cumulative risk for (a) BRCA1 carriers, (b) 
BRCA2 carriers and (c) noncarriers, corresponding to women born after 
1950. Supplementary figure S5 shows the incidence rate of ER-negative, TN, 
and CK5/6-expressing and non-expressing TN disease (only CK5/6 tested): 
incidence rate per 100,000 individuals in (a) BRCA1 carriers, (b) BRCA2 carri-
ers and (c) noncarriers, corresponding to women before after 1950. Supple-
mentary figure S6 shows the average cumulative risk for ER-negative, TN, 
and CK5/6-expressing and non-expressing TN disease (only CK5/6 tested): 
average cumulative risk for (a) BRCA1 carriers, (b) BRCA2 carriers and (c) non-
carriers, corresponding to women born after 1950. Supplementary table S1 
shows carrier mutation probabilities when the ER status of the proband is 
unknown, negative or positive. Supplementary table S2 shows carrier 
mutation probabilities when the ER status of the proband and the mother 
are unknown, negative or positive.Mavaddat et al. Breast Cancer Research 2010, 12:R28
http://breast-cancer-research.com/content/12/3/R28
Page 11 of 12
Acknowledgements
The authors thank the BCLC for pathology data. NM was funded by a scholar-
ship from the Medical Research Council. ACA is a Cancer Research-UK Senior 
Cancer Research Fellow. DFE is a CR-UK Principal Research Fellow.
Author Details
1Centre for Cancer Genetic Epidemiology, Department of Public Health and 
Primary Care, University of Cambridge, Strangeways Research Laboratory, 
Worts Causeway, Cambridge CB1 8RN, UK, 2Center for Clinical Epidemiology 
and Biostatistics, Department of Biostatistics and Epidemiology, University of 
Pennsylvania, 217 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104, 
USA and 3Molecular and Cellular Pathology, University of Queensland Centre 
for Clinical Research, Level 6 Building 71/918, University of Queensland, The 
Royal Brisbane & Women's Hospital, Herston, 4029 Brisbane, Queensland, 
Australia
References
1. Friebel TM, Domchek SM, Neuhausen SL, Wagner T, Evans DG, Isaacs C, 
Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson G, Lynch HT, Tung N, 
Blum JL, Weitzel J, Rubinstein WS, Ganz PA, Couch F, Rebbeck TR: Bilateral 
prophylactic oophorectomy and bilateral prophylactic mastectomy in 
a prospective cohort of unaffected BRCA1 and BRCA2 mutation 
carriers.  Clin Breast Cancer 2007, 7:875-882.
2. Hartmann LC, Sellers TA, Schaid DJ, Frank TS, Soderberg CL, Sitta DL, Frost 
MH, Grant CS, Donohue JH, Woods JE, McDonnell SK, Vockley CW, 
Deffenbaugh A, Couch FJ, Jenkins RB: Efficacy of bilateral prophylactic 
mastectomy in BRCA1 and BRCA2 gene mutation carriers.  J Natl Cancer 
Inst 2001, 93:1633-1637.
3. Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, 
Seynaeve C, Menke-Pluymers MB, Bartels CC, Verhoog LC, van den 
Ouweland AM, Niermeijer MF, Brekelmans CT, Klijn JG: Breast cancer after 
prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 
mutation.  N Engl J Med 2001, 345:159-164.
4. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, 
Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL: Prophylactic 
oophorectomy in carriers of BRCA1 or BRCA2 mutations.  N Engl J Med 
2002, 346:1616-1622.
5. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van't Veer L, Garber JE, 
Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL: 
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 
and BRCA2 mutation carriers: the PROSE Study Group.  J Clin Oncol 
2004, 22:1055-1062.
6. Rebbeck TR, Kauff ND, Domchek SM: Meta-analysis of risk reduction 
estimates associated with risk-reducing salpingo-oophorectomy in 
BRCA1 or BRCA2 mutation carriers.  J Natl Cancer Inst 2009, 101:80-87.
7. Antoniou AC, Easton DF: Risk prediction models for familial breast 
cancer.  Future Oncol 2006, 2:257-274.
8. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, Van De 
Vijver MJ, Farid LM, Venter D, Antoniou A, Storfer-Isser A, Smyth E, Steel 
CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, 
McManus R, Scherneck S, Ponder BA, Ford D, Peto J, Stoppa-Lyonnet D, 
Bignon YJ, Struewing JP, Spurr NK, Bishop DT, Klijn JG, Devilee P, et al.: 
Multifactorial analysis of differences between sporadic breast cancers 
and cancers involving BRCA1 and BRCA2 mutations.  J Natl Cancer Inst 
1998, 90:1138-1145.
9. Lakhani SR: The pathology of familial breast cancer: morphological 
aspects.  Breast Cancer Res 1999, 1:31-35.
10. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, 
McGuffog L, Easton DF: The pathology of familial breast cancer: 
predictive value of immunohistochemical markers estrogen receptor, 
progesterone receptor, HER-2, and p53 in patients with mutations in 
BRCA1 and BRCA2.  J Clin Oncol 2002, 20:2310-2318.
11. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry 
S, Bishop T, Benitez J, Rivas C, Bignon YJ, Chang-Claude J, Hamann U, 
Cornelisse CJ, Devilee P, Beckmann MW, Nestle-Kramling C, Daly PA, 
Haites N, Varley J, Lalloo F, Evans G, Maugard C, Meijers-Heijboer H, Klijn 
JG, Olah E, Gusterson BA, Pilotti S, Radice P, Scherneck S, Sobol H, et al.: 
Prediction of BRCA1 status in patients with breast cancer using 
estrogen receptor and basal phenotype.  Clin Cancer Res 2005, 
11:5175-5180.
12. Lynch BJ, Holden JA, Buys SS, Neuhausen SL, Gaffney DK: Pathobiologic 
characteristics of hereditary breast cancer.  Hum Pathol 1998, 
29:1140-1144.
13. Cortesi L, Turchetti D, Bertoni C, Bellei R, Mangone L, Vinceti M, Federico 
M, Silingardi V, Ferrari S: Comparison between genotype and phenotype 
identifies a high-risk population carrying BRCA1 mutations.  Genes 
Chromosomes Cancer 2000, 27:130-135.
14. Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A, Hutchins 
AM, Dite GS, McCredie MR, Giles GG, Hopper JL, Venter DJ: Distinct 
molecular pathogeneses of early-onset breast cancers in BRCA1 and 
BRCA2 mutation carriers: a population-based study.  Cancer Res 1999, 
59:2011-2017.
15. Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, Tung N, 
Olopade OI, Weber BL, McLennan J, Olivotto IA, Begin LR, Narod SA: 
Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: 
the influence of age, grade, and histological type.  Clin Cancer Res 2004, 
10:2029-2034.
16. Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A, Rodriguez S, 
Cigudosa JC, Diez O, Alonso C, Lerma E, Sanchez L, Rivas C, Benitez J: 
Immunohistochemical characteristics defined by tissue microarray of 
hereditary breast cancer not attributable to BRCA1 or BRCA2 
mutations: differences from breast carcinomas arising in BRCA1 and 
BRCA2 mutation carriers.  Clin Cancer Res 2003, 9:3606-3614.
17. Karp SE, Tonin PN, Begin LR, Martinez JJ, Zhang JC, Pollak MN, Foulkes WD: 
Influence of BRCA1 mutations on nuclear grade and estrogen receptor 
status of breast carcinoma in Ashkenazi Jewish women.  Cancer 1997, 
80:435-441.
18. Lidereau R, Eisinger F, Champeme MH, Nogues C, Bieche I, Birnbaum D, 
Pallud C, Jacquemier J, Sobol H: Major improvement in the efficacy of 
BRCA1 mutation screening using morphoclinical features of breast 
cancer.  Cancer Res 2000, 60:1206-1210.
19. Eisinger F, Nogues C, Guinebretiere JM, Peyrat JP, Bardou VJ, Noguchi T, 
Vennin P, Sauvan R, Lidereau R, Birnbaum D, Jacquemier J, Sobol H: Novel 
indications for BRCA1 screening using individual clinical and 
morphological features.  Int J Cancer 1999, 84:263-267.
20. Loman N, Johannsson O, Bendahl PO, Borg A, Ferno M, Olsson H: Steroid 
receptors in hereditary breast carcinomas associated with BRCA1 or 
BRCA2 mutations or unknown susceptibility genes.  Cancer 1998, 
83:310-319.
21. Osin PP, Lakhani SR: The pathology of familial breast cancer: 
immunohistochemistry and molecular analysis.  Breast Cancer Res 1999, 
1:36-40.
22. Johannsson OT, Idvall I, Anderson C, Borg A, Barkardottir RB, Egilsson V, 
Olsson H: Tumour biological features of BRCA1-induced breast and 
ovarian cancer.  Eur J Cancer 1997, 33:362-371.
23. Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, Risch 
HA, Eyfjord JE, Hopper JL, Southey MC, Olsson H, Johannsson O, Borg A, 
Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver 
H, Warner E, Lubinski J, Gronwald J, Gorski B, Tryggvadottir L, Syrjakoski K, 
Kallioniemi OP, Eerola H, Nevanlinna H, Pharoah PD, et al.: The BOADICEA 
model of genetic susceptibility to breast and ovarian cancers: updates 
and extensions.  Br J Cancer 2008, 98:1457-1466.
24. Antoniou AC, Pharoah PP, Smith P, Easton DF: The BOADICEA model of 
genetic susceptibility to breast and ovarian cancer.  Br J Cancer 2004, 
91:1580-1590.
25. Antoniou AC, Easton DF: Models of genetic susceptibility to breast 
cancer.  Oncogene 2006, 25:5898-5905.
26. Antoniou AC, Hardy R, Walker L, Evans DG, Shenton A, Eeles R, Shanley S, 
Pichert G, Izatt L, Rose S, Douglas F, Eccles D, Morrison PJ, Scott J, Zimmern 
RL, Easton DF, Pharoah PD: Predicting the likelihood of carrying a BRCA1 
or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad 
and the Manchester scoring system using data from UK genetics 
clinics.  J Med Genet 2008, 45:425-431.
27. Surveillance, Epidemiology, and End Results (SEER) Program Limited-
Use Data (1973-2006)   [http://www.seer.cancer.gov]
28. Lange K: An approximate model of polygenic inheritance.  Genetics 
1997, 147:1423-1430.
29. Doll R, Payne P, Waterhouse AJ: Cancer Incidence in Five Continents Volume 
I. Berlin: Springer-Verlag; 1966. 
Received: 22 January 2010 Revised: 4 May 2010 
Accepted: 18 May 2010 Published: 18 May 2010
This article is available from: http://breast-cancer-research.com/content/12/3/R28 © 2010 Mavaddat et al.; licensee BioMed Central Ltd.  This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Breast Cancer Research 2010, 12:R28Mavaddat et al. Breast Cancer Research 2010, 12:R28
http://breast-cancer-research.com/content/12/3/R28
Page 12 of 12
30. Doll R, Muir CS, Waterhouse AJ: Cancer Incidence in Five Continents Volume 
II. Geneva: UICC; 1970. 
31. Muir C, Waterhouse JAH, Mack TM, Powell J, Whelan S: Cancer Incidence in 
Five Continents Volume V. Lyon: IARC Scientific Publications; 1987. 
32. Parkin DM, Muir CS, Whelan S, Gao YT, Ferlay J, Powell J: Cancer Incidence 
in Five Continents Volume VI. Lyon: IARC Scientific Publications; 1992. 
33. Parkin DM, Whelan S, Ferlay J, Teppo L, Thomas DB: Cancer Incidence in Five 
Continents Volume VIII. Lyon: IARC Scientific Publications; 2002. 
34. Waterhouse JAH, Muir C, Shanmugaratnam K, Powell J: Cancer Incidence in 
Five Continents Volume IV. Lyon: IARC Scientific Publications; 1982. 
35. Waterhouse JAH, Muir C, Correa P, Powell J: Cancer Incidence in Five 
Continents Volume VIII. Lyon: IARC Scientific Publications; 1976. 
36. Lange K, Weeks D, Boehnke M: Programs for pedigree analysis: MENDEL, 
FISHER, and dGENE.  Genet Epidemiol 1988, 5:471-472.
37. Allred DC, Harvey JM, Berardo M, Clark GM: Prognostic and predictive 
factors in breast cancer by immunohistochemical analysis.  Mod Pathol 
1998, 11:155-168.
38. Gown AM: Current issues in ER and HER2 testing by IHC in breast 
cancer.  Mod Pathol 2008, 21(Suppl 2):S8-S15.
39. Harvey JM, Clark GM, Osborne CK, Allred DC: Estrogen receptor status by 
immunohistochemistry is superior to the ligand-binding assay for 
predicting response to adjuvant endocrine therapy in breast cancer.  J 
Clin Oncol 1999, 17:1474-1481.
40. Anderson WF, Chatterjee N, Ershler WB, Brawley OW: Estrogen receptor 
breast cancer phenotypes in the Surveillance, Epidemiology, and End 
Results database.  Breast Cancer Res Treat 2002, 76:27-36.
41. Gervaz P, Bouzourene H, Cerottini JP, Chaubert P, Benhattar J, Secic M, 
Wexner S, Givel JC, Belin B: Dukes B colorectal cancer: distinct genetic 
categories and clinical outcome based on proximal or distal tumor 
location.  Dis Colon Rectum 2001, 44:364-372.
42. Azzoni C, Bottarelli L, Campanini N, Di CG, Bader G, Mazzeo A, Salvemini C, 
Morari S, Di MD, Donadei E, Roncoroni L, Bordi C, Sarli L: Distinct 
molecular patterns based on proximal and distal sporadic colorectal 
cancer: arguments for different mechanisms in the tumorigenesis.  Int J 
Colorectal Dis 2007, 22:115-126.
43. Chapman JM, Onnie CM, Prescott NJ, Fisher SA, Mansfield JC, Mathew CG, 
Lewis CM, Verzilli CJ, Whittaker JC: Searching for genotype-phenotype 
structure: using hierarchical log-linear models in Crohn disease.  Am J 
Hum Genet 2009, 84:178-187.
44. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, 
Sherman ME: Etiology of hormone receptor-defined breast cancer: a 
systematic review of the literature.  Cancer Epidemiol Biomarkers Prev 
2004, 13:1558-1568.
45. Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Goldgar 
DE: An international initiative to identify genetic modifiers of cancer 
risk in BRCA1 and BRCA2 mutation carriers: the Consortium of 
Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA).  Breast Cancer 
Res 2007, 9:104.
46. National Institute for Clinical Excellence: Clinical Guideline 14. Familial 
breast cancer: the classification and care of women at risk of familial 
breast cancer in primary, secondary and tertiary care.  In Guidelines 
Manual London: NICE; 2004. 
47. Britton JA, Gammon MD, Schoenberg JB, Stanford JL, Coates RJ, Swanson 
CA, Potischman N, Malone KE, Brogan DJ, Daling JR, Brinton LA: Risk of 
breast cancer classified by joint estrogen receptor and progesterone 
receptor status among women 20-44 years of age.  Am J Epidemiol 2002, 
156:507-516.
48. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE: Risk factors 
for breast cancer according to estrogen and progesterone receptor 
status.  J Natl Cancer Inst 2004, 96:218-228.
49. Cotterchio M, Kreiger N, Theis B, Sloan M, Bahl S: Hormonal factors and 
the risk of breast cancer according to estrogen- and progesterone-
receptor subgroup.  Cancer Epidemiol Biomarkers Prev 2003, 
12:1053-1060.
50. Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG: 
Hormone-related factors and risk of breast cancer in relation to 
estrogen receptor and progesterone receptor status.  Am J Epidemiol 
2000, 151:703-714.
51. Rosenberg LU, Einarsdottir K, Friman EI, Wedren S, Dickman PW, Hall P, 
Magnusson C: Risk factors for hormone receptor-defined breast cancer 
in postmenopausal women.  Cancer Epidemiol Biomarkers Prev 2006, 
15:2482-2488.
52. Rusiecki JA, Holford TR, Zahm SH, Zheng T: Breast cancer risk factors 
according to joint estrogen receptor and progesterone receptor status.  
Cancer Detect Prev 2005, 29:419-426.
53. Welsh ML, Buist DS, Aiello Bowles EJ, Anderson ML, Elmore JG, Li CI: 
Population-based estimates of the relation between breast cancer risk, 
tumor subtype, and family history.  Breast Cancer Res Treat 2009, 
114:549-558.
54. Yang XR, Pfeiffer RM, Garcia-Closas M, Rimm DL, Lissowska J, Brinton LA, 
Peplonska B, Hewitt SM, Cartun RW, Mandich D, Sasano H, Evans DB, 
Sutter TR, Sherman ME: Hormonal markers in breast cancer: 
coexpression, relationship with pathologic characteristics, and risk 
factor associations in a population-based study.  Cancer Res 2007, 
67:10608-10617.
55. Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, 
Bojesen SE, Nordestgaard BG, Axelsson CK, Arias JI, Milne RL, Ribas G, 
Gonzalez-Neira A, Benitez J, Zamora P, Brauch H, Justenhoven C, Hamann 
U, Ko YD, Bruening T, Haas S, Dork T, Schurmann P, Hillemanns P, 
Bogdanova N, Bremer M, Karstens JH, Fagerholm R, Aaltonen K, et al.: 
Heterogeneity of breast cancer associations with five susceptibility loci 
by clinical and pathological characteristics.  PLoS Genet 2008, 
4:e1000054.
56. Garcia-Closas M, Chanock S: Genetic susceptibility loci for breast cancer 
by estrogen receptor status.  Clin Cancer Res 2008, 14:8000-8009.
57. Stacey SN, Manolescu A, Sulem P, Rafnar T, Gudmundsson J, Gudjonsson 
SA, Masson G, Jakobsdottir M, Thorlacius S, Helgason A, Aben KK, Strobbe 
LJ, Albers-Akkers MT, Swinkels DW, Henderson BE, Kolonel LN, Le ML, 
Millastre E, Andres R, Godino J, Garcia-Prats MD, Polo E, Tres A, Mouy M, 
Saemundsdottir J, Backman VM, Gudmundsson L, Kristjansson K, 
Bergthorsson JT, Kostic J, et al.: Common variants on chromosomes 2q35 
and 16q12 confer susceptibility to estrogen receptor-positive breast 
cancer.  Nat Genet 2007, 39:865-869.
58. Stacey SN, Manolescu A, Sulem P, Thorlacius S, Gudjonsson SA, Jonsson 
GF, Jakobsdottir M, Bergthorsson JT, Gudmundsson J, Aben KK, Strobbe 
LJ, Swinkels DW, van Engelenburg KC, Henderson BE, Kolonel LN, Le ML, 
Millastre E, Andres R, Saez B, Lambea J, Godino J, Polo E, Tres A, Picelli S, 
Rantala J, Margolin S, Jonsson T, Sigurdsson H, Jonsdottir T, Hrafnkelsson J, 
et al.: Common variants on chromosome 5p12 confer susceptibility to 
estrogen receptor-positive breast cancer.  Nat Genet 2008, 40:703-706.
59. Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA, Schmutzler 
RK, Versmold B, Engel C, Meindl A, Arnold N, Hofmann W, Sutter C, 
Niederacher D, Deissler H, Caldes T, Kampjarvi K, Nevanlinna H, Simard J, 
Beesley J, Chen X, Neuhausen SL, Rebbeck TR, Wagner T, Lynch HT, Isaacs 
C, Weitzel J, Ganz PA, Daly MB, Tomlinson G, Olopade OI, et al.: Common 
breast cancer-predisposition alleles are associated with breast cancer 
risk in BRCA1 and BRCA2 mutation carriers.  Am J Hum Genet 2008, 
82:937-948.
60. Antoniou AC, Pharoah PD, McMullan G, Day NE, Ponder BA, Easton D: 
Evidence for further breast cancer susceptibility genes in addition to 
BRCA1 and BRCA2 in a population-based study.  Genet Epidemiol 2001, 
21:1-18.
doi: 10.1186/bcr2576
Cite this article as: Mavaddat et al., Incorporating tumour pathology infor-
mation into breast cancer risk prediction algorithms Breast Cancer Research 
2010, 12:R28